Usefulness of classic cytogenetic testing compared to fluorescence in situ hybridization in genetic diagnosis of 58 patients with myelodysplastic syndromes

Polskie Archiwum Medycyny Wewnetrznej

Volumn 119, Issue 6, 2009, Pages 366-372

  Skonieczka, Katarzyna ^a   Duszeńko, Ewa ^b   Wyrowińska, Elzbieta ^c   Haus, Olga ^a,b  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Chromosome aberrations; Classical cytogenetics; Fluorescence in situ hybridization; Myelodysplastic syndromes

Indexed keywords

TRYPSIN;

ARTICLE; BONE MARROW CELL; CHROMOSOME ABERRATION; CONTROLLED STUDY; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GIEMSA STAIN; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MOLECULAR PROBE; MYELODYSPLASTIC SYNDROME; PROGNOSIS;

EID: 67650462718     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.711     Document Type: Article

References (27)

1. Panani AD, Roussos C. Cytogenetic aspects of adult primary myelodysplastic syndromes: Clinical implications. Cancer Lett. 2006; 235: 177-190.
2. Raskind W, Steinmann L, Najfeld V. Clonal development of myeloproliferative disorders: clues to hematopoietic differentiation and multistep pathogenesis of cancer. Leukemia. 1998; 12: 108-116. (Pubitemid 28108059)
3. Van Lom K, Hagemeijer A, Vandekerckhove F, et al. Cytogenetic clonality analysis: typical patterns in myelodysplastic syndrome and acute myeloid leukaemia. Brit J Haematol. 1996; 93: 594-600. (Pubitemid 26167367)
4. Bennett JM, Komrokji RS. The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment. Hematology. 2005; 10: 258-269. (Pubitemid 41825739)
5. Hellström-Lindberg E. Strategies for biology and molecular-based treatment of myelodysplastic syndromes. Curr Drug Target. 2005; 6: 713-725.
6. Nishino NT, Chang CH. Myelodysplastic syndromes. Clinicopathologic features, pathobiology and molecular pathogenesis. Arch Pathol Lab Med. 2005; 129: 1299-1310.
7. Rigolin GM, Rigoni R, Milani R, et al. Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype. Leukemia. 2001; 15: 1841-1847. (Pubitemid 33114989)
8. Wong KF, Hayes KJ, Leung S, Glassman AB. The relationship between age and karyotypic abnormalities in myelodysplastic syndromes. Cancer Genet Cytogenet. 1996; 88: 80-82. (Pubitemid 26160730)
9. Hoffman WK, Koeffler HP. Myelodysplastic syndrome. Ann Rev Med. 2005; 56: 1-16.
10. List AF. New approaches to the treatment of myelodysplasia. Oncology. 2002; 7: 39-49.
11. Kotlarek-Haus S, Haus O. [Myelodysplastic syndromes - from FAB to WHO classification]. Pol Arch Med Wewn. 2005; 114: 1128-1137. Polish.
12. Bain BJ. The World Health Organization classification of myeloproliferative and myelodysplastic syndromes. Curr Diagn Pathol. 2004; 10: 394-403. (Pubitemid 38987733)
13. Haus O. [The methodology and importance of cytogentic evaluation in hematology/oncology). Diagn Lab. 2001; 37 (Suppl 1): 101-106. Polish.
14. Pergament E. New molecular techniques for chromosome analysis. Clin Obstet Gyn. 2000; 14: 677-690.
15. Spurbeck JL, Adams SA, Stupca PJ, et al. Primer on medical genomics part XI: visualizing human chromosomes. Mayo Clin Proc. 2004; 79: 58-74. (Pubitemid 38018585)
16. ISCN 2005: An international system for human cytogenetic nomenclature. Shaffer LG, Tommerup N, eds. Basel. Karger, 2005.
17. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood. 2000; 96: 4075-4083.
18. Steensma DP, List AF. Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity. Mayo Clin Proc. 2005; 80: 681-698. (Pubitemid 40628827)
19. Shall W, Hélias C, Fohrer C, et al. Cytogenetic studies of a series of 43 consecutive secondary myelodysplastic syndromes/acute myeloid leukemias: conventional cytogenetics, FISH, and multiplex FISH. Cancer Genet Cytogenet. 2006; 168: 133-145.
20. Breccia M, Mancini M, Nanni M, et al. Clinical features of prognostic significance in myelodysplastic patients with normal karyotype at high risk of transformation. Leuk Res. 2005; 29: 33-39. (Pubitemid 39487906)
21. Greenberg P, Cox C, LeBeau MM, et al. International Scoring System for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89: 2079-2088. (Pubitemid 27132124)
22. Steensma DP, Bennett JM. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clinic Proc. 2006; 81: 30-56. (Pubitemid 43054324)
23. Romeo M, Chauffaille M, Silva MR, et al. Comparison of cytogenetics with FISH in 40 myelodysplastic syndrome patients. Leuk Res. 2002; 26: 993-996. (Pubitemid 35287209)
24. Beyer V, Castagné C, Mühlematter D, et al. Systematic screening at diagnosis of -5, del(5)(q31), -7, or chromosome 8 aneuploidy by interphase fluorescence in situ hybridization in 110 acute myelocytic leukemia and high-risk myelodysplastic syndrome patients: concordances and discrepancies with conventional cytogenetics. Cancer Genet Cytogenet. 2004; 152: 29-41.
25. Ketterling RP, Wyatt WA, VanWier SA, et al. Primary myelodysplastic syndrome with normal cytogenetics: utility of "FISH panel testing" and M-FISH. Leuk Res. 2002; 26: 235-240. (Pubitemid 34037019)
26. Cherian S, Bagg A. The genetics of the myelodysplastic syndromes: classical cytogenetics and recent molecular insights. Hematology. 2006; 11: 1-13. (Pubitemid 43354954)
27. Cherry AM, Brockman SR, Paternoster SF, et al. Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study. Leuk Res. 2003; 27: 1085-1090. (Pubitemid 36960027)